Klinikverbund Allgaeu gGmbH
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The oncology department at Klinikverbund Allgaeu gGmbH is conducting studies that aim to improve outcomes for patients with blood‑related cancers, focusing on innovative therapies and better diagnostic markers.
- Multiple myeloma
- Waldenström’s macroglobulinemia
- Advanced stage Hodgkin lymphoma
- Myelofibrosis
Across 31 active trials led by 15 investigators, researchers are evaluating novel drug combinations, maintenance strategies, and precision‑medicine approaches to increase remission rates and extend survival.
Neoplasms
In the field of solid tumors, the site is testing new targeted agents and immunotherapies to enhance treatment effectiveness for a variety of cancers.
- Advanced non‑small cell lung cancer
- Triple‑negative breast cancer
- Estrogen receptor‑positive HER2‑negative breast cancer
- Gastroesophageal junction adenocarcinoma
- Colorectal cancer (colon and rectal)
- Gynecological cancers (ovarian, peritoneal, fallopian tube)
The trials seek to compare novel agents such as antibody‑drug conjugates, checkpoint inhibitors, and KRAS‑targeted therapies against standard regimens, with goals of improving progression‑free and overall survival.
Respiratory Tract Diseases
Research on lung and respiratory conditions includes efforts to refine immunotherapy and targeted treatment options for patients with difficult‑to‑treat disease subtypes.
- KRAS‑mutated non‑small cell lung cancer
- EGFR‑mutated non‑small cell lung cancer
- Small‑cell lung cancer
- Preterm infants with respiratory distress syndrome
With a portfolio of 31 clinical trials, investigators are exploring combinations of novel agents, assessing biomarkers such as PD‑L1 expression, and evaluating strategies to reduce toxicity while extending patient survival.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 89 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 88 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1AstraZeneca AB2active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikverbund Allgaeu gGmbH
lock Showing 1 of 42 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors | Geron Corp. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 89 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 13 | Unknown | 2018-06-13 | 2026-02-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.